Member Info for Marmited

It could easily, remember Paraytec have worked with partners such as Astra Zeneca, GlaxoSmithKline on the ‘ Towards a condensed platform for aggregation profiling” program completed in 2020. Also the UK Government tasked these two giant companies to help them with tests for Covid so we are certainly not strangers by any measure.

Ha! Beat me to that point Blanka!

I don’t think many beyond BRH get it. LFT’s are make do’s because the current alternative test is PCR up to 48hrs to result. We use LFT’s because we have too as speed is considered extremely important too.
Our device has been mentioned to be able to compete with PCR’s at a whopping great speed of under 2 minutes! It also knocks off 13 minutes off of the quickest LFT’s.

(Hellooooo... wakey wakey market!! But I can wait so take the time you need!)

Worth considering.
This share began its Covid test journey from a very low valuation, it seems to have stumbled onto a device that looks set to become market leading due to speed, scale, accuracy, sensitivity with automated non clinical ease of use. It is very different from DIY home use LFT’s. It is a device which ‘should’ replace LFT’s beyond the home, it ‘should’ replace less reliable LFT’s for Asymptotic testing as these devices are designed for infectious state, not pre and post. It ‘should’ replace LFT’s for post infection testing and it is so good it ‘could’ replace LFT’s for infectious testing.

Carl on Twitter ‘We can just turn the sensitivity up or down depending on what the customer wants’.

So how does one place a value on something that looks set to lead the field in these key areas I have mentioned? Looking at current competition (not even sure they are competition?) we get much much higher market caps. To suggest we could become worth half of ODX is more than 100% increase.. that would be ramping. To suggest we become worth half of AVCT at 10x our current value would therefore super ramping.

So, a question.. are we way undervalued or are they way overvalued? Perhaps it is both? Who knows? The market will decide.

I do Compare market caps such as AVCT and ODX.

AVCT £640m
ODX £133m
BRH £30m

Ramping does put people off, personally not a fan and I normally run a mile.. however.. there is always exception to the rule.

And this is the nuts and bolts of how our device will have a future over throw away LFT’s. Say some ridiculous miracle happened and Covid disappeared tomorrow, all current LFT’s would be 100% useless for preparation and stock piling for the next Pathogen to hit the world, however, our magic box stock piled would just need an Aptamer developed and away we go! Mass testing at scale. 100’s of 1000’s of these magic boxes deployed around the world will offer the human race an accurate and super fast global defence system which can be interconnected for live global tracking, nation tracking and local tracking.

Ah, missed it!

New testing strategy can speed up COVID-19 test results for healthcare workers

"Pooling becomes increasingly useful as the population prevalence of SARS-CoV-2 decreases," Prof. Black and Dr. McDermott observed. "Initially the most conservative matrix, 250 samples, should be used to determine the prevalence level. As the prevalence falls, the use of less tolerant but higher throughput assays could be used, such as the 700 sample pool."

https://www.eurekalert.org/pub_releases/2021-04/e-nts042621.php

Serious global partners already in place..

Paraytec Tweet

14:37 - 12th April 2021

Paraytec has developed its unique patented technology over a number of years and has pursued a strategy of forming partnerships with international companies,such as Malvern Instruments & Pion Inc to manufacture and distribute its image detectors worldwide

https://twitter.com › status › photo@paraytec1 on Twitter: "Paraytec has developed its unique patented ...

But why stop there? What if that additional device was set to examine samples with a variety of fluorescence colours attached to different mutations via labeled Aptamers? In less than an additional 120 seconds the NHS track and trace could be notified via 5G not only positive cases but also the variant.

Just carry out a second test on a separate device to save hold ups with those in question and it’s still 10 mins quicker than the quickest LFT.

Agree, non clinical use is a fundamental basic in the design of our device.

Britain's medical regulator has accused ministers of 'stretching' its approval of controversial lateral flow tests for coronavirus.

The Medicines and Healthcare products Regulatory Agency (MHRA) warned the way they are currently being used risks infected people assuming they are clear and safe to mingle with others.

The Government has been criticised for rolling the lateral flow devices out for people to do themselves, despite manufacturers admitting they are built for professional use and on people with symptoms. 

Numerous studies have shown the kits are far less accurate when self-administered and leaked Department of Health emails earlier this month revealed senior officials fear they only pick up on 10 per cent of infections when done this way.

https://www.google.co.uk/amp/s/www.dailymail.co.uk/news/article-9511583/amp/Britains-drugs-watchdog-accuses-No10-stretching-approval-rules-lateral-flow-tests.html

The reality is that the magical thinking displayed by the Indian prime minister Narendra Modi’s government – which claimed the pandemic was in its “endgame” in March as the country careened towards a second wave of infections – was not much different from the mistakes of other leaders, including the former US president Donald Trump, who thought the virus would simply disappear, or the mistaken boosterism of the UK prime minister, Boris Johnson.

What is different in India – a country with a fragile health system and even weaker surveillance – is the huge possibility for harm locally and globally, perhaps on a scale not yet seen in the pandemic.

https://www.google.co.uk/amp/s/amp.theguardian.com/world/2021/apr/25/the-world-must-act-indias-covid-crisis-is-a-dire-problem-for-us-all

Yeah, it’s just another tool to help. I agree with Daprophet in that this is certainly volatile and looking at a 3 month graph it would be hard to gauge anything really, it is easy to suggest repeating pump and dump scenarios as it’s all over the place (got to love aim!) but stepping back further a more solid upward methodical picture/path emerges.

Look at the 1 year chart.

Can it continue its upward trend? Yeah! We know our Professor is super, super, super confident sharing images of a single whole virus particle, we know Paraytec are turning the test into a commercial product due to the job advert, we know it has beaten expectations that were already set extremely high, we know the world desperately needs this very different ground breaking tech for a multitude of reasons. Super fast, super accurate, cost effective due to matrix and re-use, easy to use/automated non clinical use.

Well, charts say an upward trend which began in Nov, a couple of large spikes which of course led to people cashing in, they usually do, but upward trend continues none the less.

The authors say there is a “disconnect” between the prescribed testing regime and its real-life context, which “risks an increase in staff dissatisfaction and its attendant potential for increased staff turnover and burnout” if not addressed.

They write: “Without addressing the contextual and human factors that lead to poor adherence of testing protocols, these testing regimes will not have the opportunity to perform at the required level to prevent outbreaks in care homes.”

He added: “I think the need to carry on having very robust testing is going to be with us for a very long time.
“And I think we have a duty of care to make sure that that testing is optimum.

“Our research suggests that there are lots of problems with the existing testing system that need to be resolved quickly.”

Liz Jones, policy director at the National Care Forum, said the research highlights “really key points” for the shaping of longer-term surveillance measures in care homes.

She said: “It illustrates the reality of the current testing regime in terms of time, complexity and cost, as well as the challenges of making it work with variable shift patterns, staff rotas, training and space to conduct testing.

https://www.google.co.uk/amp/s/www.independent.co.uk/news/uk/home-news/care-home-lateral-flow-test-study-b1832343.html%3famp

Meanwhile you say on AVCT

‘ Can't think of a company that has so much future potential... License to print money... ’

Is it a £600m bubble over there? Cough!